Connection

VINCENT TAM to Gram-Negative Bacterial Infections

This is a "connection" page, showing publications VINCENT TAM has written about Gram-Negative Bacterial Infections.
  1. Validation of a model to predict the risk of nephrotoxicity in patients receiving colistin. Antimicrob Agents Chemother. 2014 Nov; 58(11):6946-8.
    View in: PubMed
    Score: 0.445
  2. Independent predictors for mortality in patients with positive Stenotrophomonas maltophilia cultures. Ann Acad Med Singap. 2008 Oct; 37(10):826-30.
    View in: PubMed
    Score: 0.296
  3. Polymyxin B: a new strategy for multidrug-resistant Gram-negative organisms. Expert Opin Investig Drugs. 2008 May; 17(5):661-8.
    View in: PubMed
    Score: 0.288
  4. Pharmacokinetics of polymyxin B1 in patients with multidrug-resistant Gram-negative bacterial infections. Diagn Microbiol Infect Dis. 2008 Feb; 60(2):163-7.
    View in: PubMed
    Score: 0.276
  5. The impact of multidrug resistance on the outcomes of critically ill patients with Gram-negative bacterial pneumonia. Diagn Microbiol Infect Dis. 2007 May; 58(1):99-104.
    View in: PubMed
    Score: 0.264
  6. Intraventricular or intrathecal use of polymyxins in patients with Gram-negative meningitis: a systematic review of the available evidence. Int J Antimicrob Agents. 2007 Jan; 29(1):9-25.
    View in: PubMed
    Score: 0.261
  7. Pharmacodynamics of cefepime in patients with Gram-negative infections. J Antimicrob Chemother. 2002 Sep; 50(3):425-8.
    View in: PubMed
    Score: 0.194
  8. International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). Pharmacotherapy. 2019 01; 39(1):10-39.
    View in: PubMed
    Score: 0.151
  9. Comparative Pharmacokinetic Profiling of Different Polymyxin B Components. Antimicrob Agents Chemother. 2016 11; 60(11):6980-6982.
    View in: PubMed
    Score: 0.129
  10. Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus. Lancet Infect Dis. 2015 Feb; 15(2):225-34.
    View in: PubMed
    Score: 0.113
  11. Uptake of polymyxin B into renal cells. Antimicrob Agents Chemother. 2014 Jul; 58(7):4200-2.
    View in: PubMed
    Score: 0.109
  12. Surveillance and correlation of antibiotic prescription and resistance of Gram-negative bacteria in Singaporean hospitals. Antimicrob Agents Chemother. 2010 Mar; 54(3):1173-8.
    View in: PubMed
    Score: 0.081
  13. Polymyxins: a review of the current status including recent developments. Ann Acad Med Singap. 2008 Oct; 37(10):870-83.
    View in: PubMed
    Score: 0.074
  14. Risk factors for postoperative chest wound infections due to gram-negative bacteria in cardiac surgery patients. J Chemother. 2006 Aug; 18(4):402-8.
    View in: PubMed
    Score: 0.064
  15. Polymyxin B: similarities to and differences from colistin (polymyxin E). Expert Rev Anti Infect Ther. 2007 Oct; 5(5):811-21.
    View in: PubMed
    Score: 0.017
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.